Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$137.15 USD

137.15
101,952

-0.54 (-0.39%)

Updated May 8, 2024 11:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Debanjana Dey headshot

4 Stocks to Buy in a Thriving Outpatient Home Health Industry

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.

The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant

DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Are Medical Stocks Lagging DaVita (DVA) This Year?

Here is how DaVita HealthCare (DVA) and Alcon (ALC) have performed compared to their sector so far this year.

Nalak Das headshot

Top 5 Outpatient and Home Healthcare Stocks for Solid Returns

We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.

Is DaVita (DVA) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DaVita Inc. (DVA) Hits Fresh High: Is There Still Room to Run?

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

New Strong Buy Stocks for May 6th

ROOT, SMCI, PPC, DFH and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2024.

Best Value Stocks to Buy for May 6th

DFH, DVA and BDC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 6, 2024.

DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up

DaVita's (DVA) robust segmental revenues drive its first-quarter performance.

DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 21.43% and 2.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings

Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.

What's in Store for These 5 Medical Device Stocks in Q1 Earnings?

Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.

DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know

DaVita HealthCare (DVA) concluded the recent trading session at $132.77, signifying a +0.02% move from its prior day's close.

Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 1.98% and 1.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries

Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.

Is Trending Stock DaVita Inc. (DVA) a Buy Now?

Recently, Zacks.com users have been paying close attention to DaVita HealthCare (DVA). This makes it worthwhile to examine what the stock has in store.

Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing

Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.

DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors

DaVita HealthCare (DVA) closed at $127.82 in the latest trading session, marking a +1.36% move from the prior day.

Reasons Why You Should Retain Masimo (MASI) Stock for Now

Masimo's (MASI) R&D activities raise optimism about the stock.

CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits

CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.

GE HealthCare's (GEHC) Voluson to Aid Women's Health Imaging

GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management

AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.

Intuitive Surgical (ISRG) Q1 Earnings Beat, Procedures Robust

Intuitive Surgical's (ISRG) first-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.